McKesson shares experienced a modest pullback, registering a 1.13% decline in the most recent trading session. The pullback contrasted with a broadly positive market trend, driven by sector rotation into growth names. Trading volume for McKesson was in line with its 30-day average, suggesting the move was largely sentiment-driven rather than catalyzed by company-specific news. Investors will be watching the health distributor’s upcoming earnings report, where analysts project revenue growth of approximately 5% year-over-year and adjusted EBITDA of $1.6 billion.

McKesson Ventures led a $20 million Series A round in Prudentia Sciences, a Cambridge-based developer of AI-driven due diligence tools for life-sciences dealmaking. The financing expands McKesson’s strategic footprint in digital health, bringing Prudentia’s total capital raised to $27 million following a $7 million seed round in 2024. By integrating machine-learning models that analyze clinical signals, Prudentia aims to accelerate acquisition and licensing decisions for pharma and biotech clients. McKesson Ventures President Dave Schulte highlighted that the partnership aligns with the distributor’s goal of bolstering end-to-end supply-chain intelligence and supporting emerging technologies in drug development.